Complex of sodium alginate and gelatin derivative loaded with stem cell exosomes and its application in treating ulcerative colitis
The gelatin derivatives and sodium alginate coat stem cell exosomes to form stable hydrogels, which solves the problems of limited efficacy and poor application economy in the treatment of ulcerative colitis, and achieves effective release in the colon Effect.
Patent Information
- Application Number
- CN202410140460.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-01-31
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2044-01-31
AI Technical Summary
The current stem cell exosomes have limited efficacy in the treatment of ulcerative colitis, and traditional intravenous injection leads to poor drug residues and economics. They are susceptible to digestive tract degradation when taken orally, which limits their application effect.
Gelatin derivatives are used to form a complex with sodium alginate, and the stem cell exosomes are coated through electrostatic and hydrogen bonds to form a hydrogel loaded with high doses, adjust the network cross-link density to control drug release, ensure that release is inhibited in the stomach and Treatment in colon localization.
It significantly improves the therapeutic effect of stem cell exosomes, avoids gastric acid degradation, ensures effective release of drugs in the intestines, and improves the efficacy of treating ulcerative colitis.
Smart Images

Figure CN118161622B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedicine, and in particular to a complex of sodium alginate and a gelatin derivative loaded with stem cell exosomes and an application thereof in treating ulcerative colitis. Background Art
[0002] Ulcerative colitis is a chronic nonspecific inflammatory disease characterized by repeated attacks and remissions of intestinal mucosal inflammation. The lesions often begin in the rectum and extend to the proximal colon, which can involve the entire colon and even the terminal ileum. The main clinical manifestations are diarrhea, bloody and mucous stools, weight loss, tenesmus, etc. Among them, the imbalance of immune function caused by the destruction of the balance between immune response and immune tolerance is considered to be an important factor in ulcerative colitis.
[0003] More and more studies have shown that human umbilical cord mesenchymal stem cell (HucMSC) transplantation is an effective method for treating ulcerative colitis. HucMSC is not only rich in sources, but also not subject to ethical restrictions. Studies have shown that MSCs can regulate inflammation by regulating the polarization of macrophages, but mesenchymal stem cell transplantation still has risks such as rejection and poor differentiation, and its exosomes (Human umbilicalcord mesenchymal stem cell derived exosomes, HucMSC-Exo) can avoid these risks. HucMSC-Exo is a lipid bilayer structure vesicle actively secreted by HucMSC, with a diameter of about 40~200 nm, containing a variety of functional biological molecules, which can communicate with adjacent cells through exocytosis and exert anti-inflammatory and antioxidant biological effects.
[0004] Currently, the efficacy of HucMSC-Exo in treating ulcerative colitis is limited. How to further improve the efficacy of HucMSC-Exo is one of the problems to be solved in this field.
[0005] In view of this, the present invention is proposed. Summary of the invention
[0006] The object of the present invention is to provide a complex of sodium alginate and a gelatin derivative loaded with stem cell exosomes and an application thereof in treating ulcerative colitis.
[0007] The present invention is achieved in that:
[0008] In a first aspect, an embodiment of the present invention provides a method for preparing a hydrogel loaded with stem cell exosomes, comprising: mixing a gelatin derivative and sodium alginate to obtain a mixed solution; mixing the mixed solution with stem cell exosomes;
[0009] Wherein, the structural formula of the gelatin derivative is as follows:
[0010] .
[0011] In a second aspect, an embodiment of the present invention provides the use of a hydrogel loaded with stem cell exosomes prepared by the preparation method described in the aforementioned embodiment in the preparation of a product for the treatment or auxiliary treatment of ulcerative colitis.
[0012] In a third aspect, an embodiment of the present invention provides use of a composition in preparing a product for treating or assisting in the treatment of ulcerative colitis, wherein the composition comprises: a reagent for implementing the preparation method described in the aforementioned embodiment.
[0013] In a fourth aspect, an embodiment of the present invention provides a hydrogel loaded with stem cell exosomes, which is prepared by the preparation method described in the above embodiment.
[0014] The present invention has the following beneficial effects:
[0015] The gelatin derivative used in the present application introduces aldehyde groups and miconazole into the gelatin molecule, has good surface activity, and is well compatible with cells and active factors. Compared with other existing gelatin hydrogels, the gelatin derivative of the present invention carries more positive charges and is easy to form a stable complex with sodium alginate having anions. The complex is used to encapsulate stem cell exosomes, which not only protects the stem cell exosomes, but also prevents and controls the damage of gastric acid to the exosomes, and can dissolve in the intestine to release the exosomes, thereby greatly improving the therapeutic effect of stem cell exosomes on ulcerative colitis. BRIEF DESCRIPTION OF THE DRAWINGS
[0016] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings required for use in the embodiments are briefly introduced below. It should be understood that the following drawings only show certain embodiments of the present invention and therefore should not be regarded as limiting the scope. For ordinary technicians in this field, other related drawings can be obtained based on these drawings without creative work.
[0017] Figure 1 A is a syringe formed by squeezing gel, B is a sodium alginate gelatin hydrogel bead embedded with stem cell exosomes prepared in Example 1, and C is a sodium alginate gelatin hydrogel bead (similar to the sodium alginate gelatin hydrogel bead of B, except that the stem cell exosomes are not embedded);
[0018] Figure 2 The results of the release experiment of the exosome-encapsulated hydrogel beads in Experimental Example 1;
[0019] Figure 3 The results of the in vitro anti-inflammatory experiment of exosomes released by hydrogel beads in Experimental Example 1;
[0020] Figure 4 The results of the release experiment of the exosome-encapsulated hydrogel beads in Experimental Example 2;
[0021] Figure 5 These are the results of the in vitro anti-inflammatory experiment of exosomes released by hydrogel beads in Experimental Example 2. DETAILED DESCRIPTION
[0022] In order to make the purpose, technical scheme and advantages of the embodiments of the present invention clearer, the technical scheme in the embodiments of the present invention will be described clearly and completely below. If the specific conditions are not specified in the embodiments, they are carried out according to conventional conditions or conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased commercially.
[0023] The inventors of this application have found through analysis and research that the current method of administration of HucMSC-Exo is mainly intravenous injection. This method of administration causes exosomes to remain in the liver and lungs, and only a few exosomes reach the colon to exert therapeutic effects, thus limiting the application of exosomes. At the same time, intravenous injection requires specialized medical staff to operate, so the economy and portability are poor, thus limiting the application of exosomes. Direct oral exosomes can directly reach the affected part of the intestine, so that the stem cell exosomes can directly act on the intestine, thereby playing a role in repair and anti-inflammatory, but oral administration will be degraded by the digestive tract, causing the stem cell exosomes to degrade. Therefore, the present invention forms a sodium alginate-gelatin derivative complex by mixing a specific gelatin derivative hydrogel with sodium alginate, and forms electrostatic and hydrogen bonds to encapsulate the stem cell exosomes. The hydrogel can load high doses of drugs and can continuously control the release of drugs by adjusting its own network cross-linking density. Sodium alginate itself has an anionic charge, which is crucial for the stem cell exosomes to inhibit release in the stomach and thus be colon-localized for oral treatment. By forming a complex with sodium alginate and hydrogel, the embedded stem cell exosomes can better resist degradation by gastric juice, and also help them to be localized in the colon and release the exosomes, thereby greatly improving the therapeutic effect.
[0024] Specific technical solutions
[0025] On the one hand, an embodiment of the present invention provides a method for preparing a hydrogel loaded with stem cell exosomes, comprising: mixing a gelatin derivative and sodium alginate to obtain a mixed solution; mixing the mixed solution with stem cell exosomes;
[0026] Wherein, the structural formula of the gelatin derivative is as follows:
[0027] .
[0028] The gelatin derivative used in the present application introduces aldehyde groups and miconazole into the gelatin molecule, has good surface activity, and is well compatible with cells and active factors. The gelatin derivative is combined with carboxymethyl chitosan in a dynamic imine bond to prepare hydrogel microspheres. Compared with other existing gelatin hydrogels, the gelatin derivative of the present invention carries more positive charges and easily forms a stable complex with sodium alginate having anions.
[0029] The hydrogel loaded with stem cell exosomes prepared by the present invention has a more excellent three-dimensional network structure, self-repair function, controlled sustained release effect and anti-deformation ability.
[0030] In some embodiments, the mixing conditions include: 40-60° C., 10-60 min.
[0031] In some embodiments, the mixing temperature of the gelatin derivative and sodium alginate can be any one of 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60°C or a range between any two of them; the mixing time can be any one of 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60 min or a range between any two of them.
[0032] In some embodiments, in the mixed solution, the mass ratio of the gelatin derivative to the sodium alginate is 2-5:1.
[0033] In some embodiments, the mass ratio of the gelatin derivative to the sodium alginate is any one of 2:1, 3:1, 4:1, 5:1, or a range between any two of them.
[0034] In some embodiments, the stem cell exosomes are mesenchymal stem cells (MSC) exosomes. In some embodiments, the stem cell exosomes can be MSC exosomes of human origin, and the source can specifically be human bone marrow, blood, umbilical cord, placenta, fat, amniotic membrane, amniotic fluid, dental pulp, skin, menstrual blood, etc.
[0035] In some embodiments, the preparation of the gelatin derivative comprises: mixing an aqueous solution containing aldehyde-modified gelatin with a miconazole derivative, dialyzing and freeze-drying to obtain the gelatin derivative; the mixing mass ratio of the aldehyde-modified gelatin and the miconazole derivative is 20-30:6-10.
[0036] In some embodiments, the mixing mass ratio of the aldehyded gelatin and the miconazole derivative may be any one of 20:6, 25:6, 30:6, 20:8, 25:8, 30:8, 20:10, 25:10, 30:10, or a range between any two of them.
[0037] In some embodiments, sodium hydroxide and benzyltriethylammonium chloride are further added to the mixed system of the aqueous solution containing aldehyde-formylated gelatin and the miconazole derivative; the mixing mass ratio of aldehyde-formylated gelatin, sodium hydroxide and benzyltriethylammonium chloride is 20~30:1~3:0.1~3.
[0038] In some embodiments, the mass ratio of aldehyded gelatin to sodium hydroxide can be any one of 20:1, 22:1, 24:1, 26:1, 28:1, 30:1, 20:2, 22:2, 24:2, 26:2, 28:2, 30:2, 20:3, 22:3, 24:3, 26:3, 28:3, 30:3, or a range between any two of them.
[0039] In some embodiments, the mixing mass ratio of aldehyded gelatin to benzyltriethylammonium chloride can be any one of 20:0.1, 25:0.1, 30:0.1, 20:0.5, 25:0.5, 30:0.5, 20:1, 25:1, 30:1, 20:2, 25:2, 30:2, 20:3, 25:3, 30:3, or a range between any two of them.
[0040] In some embodiments, the aqueous solution containing aldehyde-modified gelatin is obtained by mixing aldehyde-modified gelatin with water at 50-70° C. The temperature can be any one of 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70° C. or a range between any two of the above.
[0041] In some embodiments, after mixing the aqueous solution containing aldehyde-modified gelatin with sodium hydroxide, miconazole derivatives and benzyltriethylammonium chloride and before dialysis, the preparation of the gelatin derivative further comprises: adjusting the pH of the mixed product to 6 to 7. The pH can be any one of 6, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7 or a range between any two of them.
[0042] In some embodiments, the dialysis comprises: using a dialysis bag with a molecular weight cutoff of 8000-14000D, the dialysis time is 60-80 hours, the deionized water is replaced every 10-14 hours, and the solution in the dialysis bag is collected and freeze-dried.
[0043] In some embodiments, the dialysis time can be any one of 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80 hours or a range between any two thereof. The time for replacing deionized water can be any one of 10, 12, 14 hours or a range between any two thereof.
[0044] In some embodiments, the preparation of the miconazole derivative comprises:
[0045] reacting a mixture of an N,N-dimethylformamide solution containing miconazole and an aqueous solution of trans-3-chloroacrylic acid at 25-35° C. for 6-10 hours to obtain a reaction mixture;
[0046] The reaction mixture is mixed with water, and after removing N,N-dimethylformamide, the miconazole derivative is obtained.
[0047] In some embodiments, the reaction temperature of the mixture consisting of the N,N-dimethylformamide solution containing miconazole and the aqueous solution of trans-3-chloroacrylic acid can be any one of 25, 26, 28, 30, 32, 34, and 35° C., or a range between any two of them; the reaction time can be any one of 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, and 10 h, or a range between any two of them.
[0048] In some embodiments, in the N,N-dimethylformamide solution containing miconazole, the concentration of miconazole is 0.1-1 g / mL. The concentration can be any one of 0.1, 0.2, 0.4, 0.6, 0.8, 1 g / mL or a range between any two thereof.
[0049] In some embodiments, in the aqueous solution of trans-3-chloroacrylic acid, the concentration of trans-3-chloroacrylic acid is 0.05-0.5 g / mL. The concentration can specifically be any one of 0.05, 0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45 and 0.5 g / mL or a range between any two thereof.
[0050] In some embodiments, the mixed molar ratio of miconazole and trans-3-chloroacrylic acid is 1:0.5 to 1. The mixed molar ratio can be any one of 1:0.5, 1:0.6, 1:0.8, 1:1, or a range between any two of them.
[0051] The present application has no special restrictions on the preparation of aldehyde-modified gelatin, and it can be prepared by existing methods or directly obtained from commercial products.
[0052] In some embodiments, the preparation of the aldehyde-modified gelatin includes: reacting an aqueous solution containing gelatin with potassium periodate in the dark for 4 to 8 hours, adding ethylene glycol to react for 0.1 to 2 hours; after dialysis, freeze-drying to obtain the aldehyde-modified gelatin.
[0053] In some embodiments, the preparation step of the aqueous solution containing gelatin includes: dispersing gelatin in water, stirring and dissolving at 55-65° C., and cooling to 25-40° C.
[0054] In some embodiments, in the aqueous solution containing gelatin, the mass ratio of gelatin to water is 1:10-30, specifically any one of 1:10, 1:15, 1:20, 1:25, 1:30 or a range between any two of them.
[0055] In some embodiments, the mixing mass ratio of gelatin to potassium periodate is 1:0.8~2, specifically any one of 1:0.8, 1:1, 1:1.2, 1:1.4, 1:1.6, 1:1.8, 1:2 or a range between any two of them.
[0056] In some embodiments, the mixing mass ratio of gelatin to ethylene glycol is 1:0.5~1.5, specifically any one of 1:0.5, 1:0.8, 1:1, 1:1.2, 1:1.4, 1:1.5 or a range between any two of them.
[0057] In some embodiments, after the gelatin derivative and sodium alginate are mixed at 40-60°C for 10-60 minutes, the preparation method further comprises standing the mixed solution (the solution after the gelatin derivative and sodium alginate are mixed) at 5-35°C for 10-60 minutes to obtain the final mixed solution. The standing temperature can be any one of 5, 10, 15, 20, 25, 30, 35°C or a range between any two thereof; the standing time can be any one of 10, 20, 30, 40, 50, 60 minutes or a range between any two thereof.
[0058] In some embodiments, the mixed amount of the mixed solution and the stem cell exosomes is: 200-600 μg of the stem cell exosomes are mixed per 1 mL of the mixed solution. Optionally, 200, 250, 300, 350, 400, 450, 500, 550 and 600 μg of the stem cell exosomes can be mixed per 1 mL.
[0059] In some embodiments, the preparation method further comprises: spraying the product obtained by mixing the mixed solution with stem cell exosomes into a calcium chloride solution to obtain hydrogel microspheres loaded with stem cell exosomes.
[0060] In some embodiments, in the calcium chloride solution, the concentration of calcium chloride can be 0.01~1M, specifically any one of 0.01, 0.05, 0.1, 0.15, 0.2, 0.4, 0.6, 0.8, 1M or a range between any two of them.
[0061] On the other hand, an embodiment of the present invention further provides the use of a hydrogel loaded with stem cell exosomes prepared by the preparation method described in any of the aforementioned embodiments in the preparation of a product for the treatment or auxiliary treatment of ulcerative colitis.
[0062] On the other hand, an embodiment of the present invention further provides use of the composition in preparing a product for treating or assisting in treating ulcerative colitis, wherein the composition comprises: a reagent for implementing the preparation method described in any of the aforementioned embodiments.
[0063] In some embodiments, the composition includes: a gelatin derivative or a raw material for preparing the gelatin derivative, stem cell exosomes and sodium alginate.
[0064] In some embodiments, the type of the product is selected from any one of a reagent, a kit, and a medicine.
[0065] "Treatment" as used herein includes preventing or alleviating a condition, reducing the rate at which a condition develops or progresses, reducing the risk of developing a condition, preventing or delaying the development of symptoms associated with a condition, reducing or terminating symptoms associated with a condition, producing complete or partial reversal of a condition, curing a condition, or a combination of the above.
[0066] For cancer, "treatment" can refer to inhibiting or slowing the growth, reproduction, or metastasis of tumors or malignant cells, or some combination of the above. For tumors, "treatment" includes eliminating all or part of the tumor, inhibiting or slowing tumor growth and metastasis, preventing or delaying the development of the tumor, or some combination of the above.
[0067] In addition, an embodiment of the present invention provides a hydrogel loaded with stem cell exosomes, which is prepared by the preparation method described in any of the above embodiments.
[0068] The features and performance of the present invention are further described in detail below in conjunction with the embodiments.
[0069] Example 1
[0070] This embodiment provides a complex of sodium alginate and a gelatin derivative loaded with stem cell exosomes and a preparation method thereof.
[0071] a. Preparation of Gelatin Derivatives
[0072] (1) Disperse gelatin in deionized water, stir and dissolve at 60°C, cool to 35°C, add potassium periodate, react in the dark for 6 hours, then add ethylene glycol, continue stirring for 0.5 hours, dialyze with a dialysis bag with a molecular weight cutoff of 8000-14000D for 72 hours, replace deionized water every 12 hours, collect the solution in the dialysis bag and freeze-dry to obtain aldehyde-modified gelatin. The mass ratio of gelatin, deionized water, potassium periodate, and ethylene glycol is 1:20:1.2:0.9;
[0073] (2) Miconazole is dissolved in N,N-dimethylformamide to obtain solution 1; trans-3-chloroacrylic acid is dissolved in deionized water to obtain solution 2; under a nitrogen atmosphere, solution 2 is added dropwise to solution 1 and stirred, and the addition is completed in 1 hour, the temperature is raised to 30°C, and stirring is continued for 8 hours to obtain a reaction mixture; deionized water is added to the reaction mixture so that the volume ratio of N,N-dimethylformamide to deionized water in the reaction mixture is 1:10, N,N-dimethylformamide is removed by rotary evaporation, and then extracted with ethyl acetate, the water layer is concentrated and dried to obtain a miconazole derivative. Among them, the mass concentration of miconazole in solution 1 is 0.20 g / mL, the mass concentration of trans-3-chloroacrylic acid in solution 2 is 0.15 g / mL, and the molar ratio of miconazole to trans-3-chloroacrylic acid is 1:0.8;
[0074] (3) Disperse the aldehyde-modified gelatin obtained in step (1) in deionized water, heat to 60°C, stir for 30 minutes, then sequentially add sodium hydroxide, the miconazole derivative obtained in step (2), and benzyltriethylammonium chloride, continue stirring for 4 hours, adjust the pH to 6-7 with hydrochloric acid, dialyze for 72 hours with a dialysis bag with a molecular weight cutoff of 8000-14000D, replace the deionized water every 12 hours, collect the solution in the dialysis bag and freeze-dry to obtain a gelatin derivative. The mass ratio of aldehyde-modified gelatin, sodium hydroxide, miconazole derivative and benzyltriethylammonium chloride is 25:1:8:0.9, and the amount of aldehyde-modified gelatin added to the deionized water is 0.15 g / mL.
[0075] The structural formula of the prepared gelatin derivative is as follows:
[0076] .
[0077] b. Preparation of gelatin derivative and sodium alginate complex to embed stem cell exosomes
[0078] The prepared gelatin derivative and sodium alginate were mixed in water at a mass ratio of 3:1 to form a mixed solution with a final concentration of 2% (w / v); the mixed solution was stirred at 50°C for 30 min to form a viscous mixture, and placed at 25°C for 30 min. 1 mL of the solution was taken, and human umbilical cord blood mesenchymal stem cell exosomes (about 400 μg) collected by centrifugation were added and mixed, and then sprayed into 0.1M 10mL CaCl2 solution through a 1ml syringe to obtain sodium alginate gelatin hydrogel beads embedded with stem cell exosomes (a complex of sodium alginate and gelatin derivatives loaded with stem cell exosomes).
[0079] Test Example 1
[0080] Sodium alginate gelatin hydrogel beads embedded with stem cell exosomes were prepared based on the preparation method provided in Example 1. At the same time, gelatin derivatives (also called hydrogel derivatives) were used to embed stem cell exosomes as a control (the preparation method is roughly the same as that in Example 1, except that sodium alginate is not added).
[0081] The results of the hydrogels prepared in Example 1 and the control group can be referred to Figure 1 .
[0082] 2. Exosome Release from Hydrogel-coated Exosomes
[0083] Simulated gastric fluid (SGF) and simulated intestinal fluid (SIF) were prepared according to the Chinese Pharmacopoeia. The prepared hydrogel beads encapsulating exosomes were placed in 1 mL PBS buffer, simulated gastric fluid, and simulated intestinal fluid, and released in a shaker at 37°C at 100 r / min. 10 μL of the released solution was taken out at fixed time points, and 10 μL of the corresponding PBS buffer (pH 7.2-7.4) and simulated intestinal fluid were supplemented at the same time.
[0084] The protein concentration of the released liquid was measured by Nanodrop One to calculate the release amount of exosomes. The calculation formula is as follows:
[0085] Cumulative release rate exosomes% = (V0C n + V e ∑ n-1 ) / m d ×100%; where V0 is the total volume of the release medium, C n is the drug concentration of the nth sampling, V e is the sampling volume each time, m d For drug content.
[0086] Results Figure 2 .
[0087] Figure 2It can be seen that in PBS solution, since the hydrogel derivatives and sodium alginate form a more stable complex, the release rate of exosomes is significantly lower than that of hydrogel sodium alginate; in simulated gastric fluid, the hydrogel derivatives of the control group have an exosome release rate of 70% to 90% in simulated gastric fluid for 30 to 120 min; while the release rate of the hydrogel beads loaded with stem cell exosomes prepared in Example 1 is maintained between 30% and 53%. It can be seen that sodium alginate gelatin hydrogel (hydrogel loaded with stem cell exosomes) can protect the exosomes from being destroyed by gastric juice to a certain extent, so that the exosomes can reach the intestine smoothly.
[0088] 3. Anti-inflammatory properties of exosomes after release
[0089] The released stem cell exosomes collected by centrifugation were dissolved in PBS, and the released exosomes collected by centrifugation were incubated with LPS-induced RAW264.7 macrophages for 24 h, and the secretion of IL-6 and TNF-a was detected by ELSIA.
[0090] Results Figure 3 .
[0091] Depend on Figure 3 It can be seen that sodium alginate gelatin hydrogel and hydrogel-embedded exosomes have a good anti-inflammatory effect on LPS-induced RAW264.7 macrophages.
[0092] Test Example 2
[0093] This embodiment provides a hydrogel loaded with stem cell exosomes and a preparation method thereof, which is substantially the same as that of Example 1, except that the gelatin derivative is replaced with other gelatin hydrogels, as described below.
[0094] a. Gelatin hydrogel preparation
[0095] 4 g of gelatin (MW ~ 200 kDa, purchased from Solebao Biotechnology) was dissolved in 40 mL of water, heated in a water bath at 50 °C, stirred until completely dissolved, filtered, and then filtered using a microporous filter membrane with a gradient of 0.8, 0.45 and 0.22 μM to obtain a gelatin hydrogel.
[0096] b. Preparation of gelatin hydrogel and sodium alginate composites to embed stem cell exosomes
[0097] The prepared gelatin hydrogel and sodium alginate were mixed in water at a mass ratio of 3:1 to form a 2% (w / v) mixed solution; the mixed solution was stirred at 50°C for 30 min to form a viscous mixture, and then placed at 25°C for 30 min. 1 mL of the solution was taken, 400 μg of stem cell exosomes collected by centrifugation were added, and the mixture was sprayed into 0.1M 10mL CaCl2 solution through a 1ml syringe to obtain sodium alginate gelatin hydrogel beads (hydrogel loaded with stem cell exosomes) embedded with stem cell exosomes.
[0098] Meanwhile, the gelatin hydrogel-embedded stem cell exosomes prepared in step a of this example was used as a control (the difference was that no sodium alginate was added).
[0099] 2. Exosome Release from Hydrogel-coated Exosomes
[0100] Simulated gastric fluid (SGF) and simulated intestinal fluid (SIF) were prepared according to the Chinese Pharmacopoeia. The prepared hydrogel beads encapsulating exosomes were placed in 1 mL PBS buffer, simulated gastric fluid, and simulated intestinal fluid, and released in a shaker at 37°C at 100 r / min. 10 μL of the released solution was taken out at fixed time points, and 10 μL of the corresponding PBS buffer (pH 7.2-7.4) and simulated intestinal fluid were supplemented at the same time.
[0101] The protein concentration of the released liquid was measured by Nanodrop One to calculate the release amount of exosomes. The calculation formula is as follows:
[0102] Cumulative release rate exosomes% = (V0C n + Ve∑ n-1 ) / md×100%; where V0 is the total volume of the release medium, C n is the drug concentration of the nth sampling, V e is the sampling volume each time, m d For drug content.
[0103] Results Figure 4 .
[0104] Figure 4 It can be seen that in PBS solution, the gelatin hydrogel in this test example and sodium alginate can also form a stable complex; in simulated gastric fluid, compared with the sodium alginate gelatin hydrogel prepared in this test example (the complex of the gelatin hydrogel loaded with stem cell exosomes and sodium alginate), the hydrogel loaded with stem cell exosomes prepared in Example 1 ( Figure 2The sodium alginate gelatin hydrogel prepared in Example 1 has a lower exosome release rate than the sodium alginate gelatin hydrogel in the experimental example, indicating that the sodium alginate gelatin hydrogel prepared in Example 1 can better resist the degradation of gastric acid and digestive enzymes in the stomach; in the simulated intestinal fluid, there is no significant difference in the release rate of exosomes between the sodium alginate gelatin hydrogel prepared in Example 1 and the sodium alginate gelatin hydrogel prepared in this experimental example. This may be due to the fact that the digestive enzymes in the intestinal fluid have no difference in the degradation of the complex formed by the two. This reflects that the sodium alginate gelatin hydrogel prepared in Example 1 can protect the stem cell exosomes from being degraded when passing through the stomach, and can release the exosomes well when arriving at the intestine.
[0105] 3. Anti-inflammatory properties of exosomes after release
[0106] The embedded exosomes were dissolved in PBS, and the released exosomes collected by centrifugation were incubated with LPS-induced RAW264.7 macrophages for 24 h. The secretion of IL-6 and TNF-a was detected by ELSIA.
[0107] Results Figure 5 .
[0108] Depend on Figure 5 It can be seen that sodium alginate gelatin hydrogel and hydrogel-embedded exosomes have a good anti-inflammatory effect on LPS-induced RAW264.7 macrophages.
[0109] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.
Claims
1. A method for preparing a hydrogel loaded with stem cell exosomes, characterized in that: It includes: mixing the gelatin derivative and sodium alginate to obtain a mixed solution; mixing the mixed solution with stem cell exosomes; Wherein, the structural formula of the gelatin derivative is as follows: 。 2. The preparation method according to claim 1, characterized in that: The mixing conditions include: 40-60° C., 10-60 min.
3. The preparation method according to claim 1, characterized in that: In the mixed solution, the mass ratio of the gelatin derivative to the sodium alginate is 2-5:
1.
4. The preparation method according to claim 1, characterized in that: The preparation of the gelatin derivative comprises: mixing an aqueous solution containing aldehyde-modified gelatin with a miconazole derivative, dialyzing and freeze-drying to obtain the gelatin derivative; the mixing mass ratio of the aldehyde-modified gelatin to the miconazole derivative is 20-30:6-10.
5. The preparation method according to claim 4, characterized in that: Sodium hydroxide and benzyltriethylammonium chloride are added to a mixed system of an aqueous solution containing aldehyde-modified gelatin and a miconazole derivative; the mixed mass ratio of the aldehyde-modified gelatin, sodium hydroxide and benzyltriethylammonium chloride is 20-30:1-3:0.1-3.
6. The preparation method according to claim 5, characterized in that: The aqueous solution containing aldehyde-modified gelatin is obtained by mixing aldehyde-modified gelatin and water at 50-70°C.
7. The preparation method according to claim 6, characterized in that: After mixing the aqueous solution containing aldehyde-modified gelatin with sodium hydroxide, miconazole derivative and benzyltriethylammonium chloride and before dialysis, the preparation of the gelatin derivative further comprises: adjusting the pH of the mixed product to 6-7.
8. The preparation method according to claim 7, characterized in that: The preparation of the miconazole derivative comprises: reacting a mixture of an N,N-dimethylformamide solution containing miconazole and an aqueous solution of trans-3-chloroacrylic acid at 25-35° C. for 6-10 hours to obtain a reaction mixture; The reaction mixture is mixed with water, and after removing N,N-dimethylformamide, the miconazole derivative is obtained.
9. The preparation method according to claim 8, characterized in that: In the N,N-dimethylformamide solution containing miconazole, the concentration of miconazole is 0.1-1 g / mL.
10. The preparation method according to claim 9, characterized in that: In the aqueous solution of trans-3-chloroacrylic acid, the concentration of trans-3-chloroacrylic acid is 0.05-0.5 g / mL.
11. The preparation method according to claim 10, characterized in that: The mixing molar ratio of miconazole and trans-3-chloroacrylic acid is 1:0.5~1.
12. The preparation method according to any one of claims 1 to 11, characterized in that: After the gelatin derivative and sodium alginate are mixed at 40-60° C. for 10-60 minutes, the preparation method further comprises allowing the mixed solution to stand at 5-35° C. for 10-60 minutes to obtain the final mixed solution.
13. The preparation method according to any one of claims 1 to 11, characterized in that: The mixed amount of the mixed solution and the stem cell exosomes is: 200-600 μg of the stem cell exosomes are mixed per 1 mL of the mixed solution.
14. The preparation method according to any one of claims 1 to 11, characterized in that: The preparation method further comprises: spraying the product obtained by mixing the mixed solution with stem cell exosomes into a calcium chloride solution to obtain hydrogel microspheres loaded with stem cell exosomes.
15. Use of the hydrogel loaded with stem cell exosomes obtained by the preparation method according to any one of claims 1 to 14 in the preparation of a product for the treatment or auxiliary treatment of ulcerative colitis.
16. A hydrogel loaded with stem cell exosomes, characterized in that: It is prepared by the preparation method according to any one of claims 1 to 14.
Citation Information
Cited By
Nasal administration preparation for cerebral diseases as well as preparation method and application of nasal administration preparation
CN120860256A
Nasal administration preparations for brain diseases, and methods for preparing and using the same
CN120860256B
Gelatin derivative microsphere coated with stem cell exosome, preparation method of gelatin derivative microsphere and application of gelatin derivative microsphere in preparation of external ophthalmic preparation
CN121265560A
Gelatin derivative microspheres coated with stem cell exosomes, method for preparing same, and use thereof in the preparation of ophthalmic preparations for external use
CN121265560B
